We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 8,016

Names Matter: The Challenge of Naming Your Brand
  • Wolters Kluwer NV
  • Global, United Kingdom, USA
  • June 16 2017

Do names really matter? They do if you're involved in trademarks, domains, or brand protection. And they've become extremely important in today's


Life sciences: product regulation and liability in China
  • Ropes & Gray LLP
  • China, Global
  • June 14 2017

A structured guide to product regulation and liability laws in China


SCOTUS Ruling Gives a Boost to Biosimilars; FDA Continues to Advance Products Through AdComs
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • June 14 2017

On a sweltering hot D.C. morning, those of us anxiously awaiting the Supreme Court’s opinion in its first case involving biosimilar biological


Life Sciences: Compliance and enforcement in Romania
  • Maravela & Asociații
  • Global, Romania
  • June 14 2017

A structured guide to compliance and dishonest practices in Romania


Supreme Court Dictates How Long Biosimilar Applicants Must Wait Before Bringing Approved Products to Market
  • Wolf Greenfield & Sacks PC
  • USA
  • June 13 2017

Over seven years after the Biologics Price Competition and Innovation Act (BPCIA) was signed into law, the Supreme Court has answered two


DOL Fiduciary RuleRecommended Action for Private Fund Managers
  • Pillsbury Winthrop Shaw Pittman LLP
  • USA
  • June 13 2017

On June 9, 2017, the Department of Labor (DOL) regulation updating the definition of “fiduciary” for purposes of ERISA became effective, along with a


FTC Settles Claims Against Trampoline Companies Over Online Reviews
  • Reed Smith LLP
  • USA
  • June 9 2017

The Federal Trade Commission ("FTC") last week agreed to settle charges levied against the marketers of Infinity and Olympus Pro brand trampolines


Convenience vs. Compliance: Behavior-Driven Marketing of Credit Products
  • Bryan Cave LLP
  • USA
  • June 9 2017

Bryan Cave colleague Ken Achenbach joined Jonathan and me on the latest Episode of The Bank Account for a discussion of the potential compliance


Ohio Attorney General Sues Pharmaceutical Companies Over Opioid Marketing - Yet Another Sign of Government Focus on Recovering Financial Cost of Opioid Epidemic
  • Pietragallo Gordon Alfano Bosick & Raspanti LLP
  • USA
  • June 9 2017

Last week, Ohio Attorney General Mike DeWine filed a lawsuit against multiple pharmaceutical companies, including Purdue, Teva, Johnson & Johnson


Maryland Enacts Landmark Drug Price Gouging Legislation; Nevada Governor Vetoes Drug Pricing Bill
  • Cooley LLP
  • USA
  • June 8 2017

Maryland became the first state to enact legislation that outlaws “price gouging” in the generic drug market. H.B. 631, enacted on May 27, 2017 (the